| Hint | Answer | % Correct |
|---|---|---|
| Component of Cryoprecipitate | 150-250 mg fibrinogen | 0%
|
| RBC Storage: Decrease | 2,3-DPG | 0%
|
| Solutions Avoided for Dilution of Blood Components | 5% dextrose solution in water | 0%
|
| Component of Cryoprecipitate | 80 U AHF/Factor VIII | 0%
|
| Blood Systems Causing HDFN | ABO | 0%
|
| Medications that Can Cause Birth Defects | Accutane | 0%
|
| CPP contains | ADAMTS13 | 0%
|
| Component of rejuvenation solution | Adenosine | 0%
|
| IUT Unit Requirements | Ag-negative for maternal RBC antibodies | 0%
|
| Immediate Immunulogic TR | Immmediate Transfusion Reactions | AHTR | 0%
|
| CPP contains | albumin | 0%
|
| Immediate Immunulogic TR | Allergic | 0%
|
| Immmediate Transfusion Reactions | Allergic or urticarial | 0%
|
| Conditions where IUT is necessary | Amniotic fluid OD 450 nm high | 0%
|
| Immediate Immunulogic TR | Anaphylactic | 0%
|
| Immmediate Transfusion Reactions | Anaphylactic or anaphylactoid | 0%
|
| Blood Systems Causing HDFN | Anti-c | 0%
|
| High titer, low avidity | anti-Ch/Rg | 0%
|
| High titer, low avidity | anti-Cs (cost) | 0%
|
| Blood Systems Causing HDFN | Anti-D | 0%
|
| Blood Systems Causing HDFN | Anti-DC | 0%
|
| Blood Systems Causing HDFN | Anti-DE | 0%
|
| Blood Systems Causing HDFN | Anti-Duffy | 0%
|
| High titer, low avidity | anti-JMH | 0%
|
| Blood Systems Causing HDFN | Anti-Kell | 0%
|
| Blood Systems Causing HDFN | Anti-Kidd | 0%
|
| High titer, low avidity | anti-Kn | 0%
|
| High titer, low avidity | anti-McCoy | 0%
|
| High titer, low avidity | anti-Yk (york) | 0%
|
| Criteria to be Eligible for Computer Crossmatch | at least 2 concordant ABO typing results | 0%
|
| Platelet Storage Decrease | RBC Storage: Decrease | ATP | 0%
|
| HPA Common in Blacks | Augustine | 0%
|
| High Prevalence Antigen | Augustine (Ata) | 0%
|
| Medications that Can Cause Birth Defects | Avodart | 0%
|
| Parasites that can be Transmitted through Transfusion | Babesia | 0%
|
| Erythrocytapheresis indications | Babesiosis | 0%
|
| Immediate Non-Immunulogic TR | Bacterial contamination | 0%
|
| Immmediate Transfusion Reactions | Bacterial contamination or sepsis | 0%
|
| Antiplatelet Agent | Brilinta | 0%
|
| Population at risk of TA-GVHD | Cancer | 0%
|
| Additional Red Cell Procedures in Antibody Identification | Cell Separation Technique | 0%
|
| Additional Red Cell Procedures in Antibody Identification | Chloroquine diphosphate | 0%
|
| IUT Unit Requirements | CMV-negative | 0%
|
| What to do during transfusion reaction? | Contact treating physician | 0%
|
| Conditions where IUT is necessary | Cord blood sample <10 g/dL | 0%
|
| High Prevalence Antigen | Crome (Cra) | 0%
|
| HPA Common in Blacks | Cromer | 0%
|
| CPP is deficient in | cryoglobulin | 0%
|
| Prevention and Treatment of Hemosiderosis | Deferroxamine | 0%
|
| Platelet Storage Increase | Degranulation (B-thromboglobulin, platelet factor 4) | 0%
|
| Prevention and Treatment of Hemosiderosis | Desferioxamine | 0%
|
| Delayed Immunologic TR | Delayed Transfusion Reactions | DHTR | 0%
|
| Penetrating agents | Dimethylsulfoxide | 0%
|
| Delayed Non-Immunologic TR | Disease transmission | 0%
|
| Donation Process | Donor registration | 0%
|
| Donation Process | Donor selection and blood collection | 0%
|
| Antiplatelet Agent | Effient | 0%
|
| Additional Red Cell Procedures in Antibody Identification | Elution | 0%
|
| High Prevalence Antigen | Ena | 0%
|
| Additional Red Cell Procedures in Antibody Identification | Enzyme Treatment | 0%
|
| Component of Cryoprecipitate | Factor XIII | 0%
|
| Antiplatelet Agent | Feldene | 0%
|
| Conditions where IUT is necessary | Fetal hydrops | 0%
|
| CPP cannot be used as a substitute for | FFP | 0%
|
| Component of Cryoprecipitate | Fibronectin | 0%
|
| CPP is deficient in | fibronectin | 0%
|
| Immediate Immunulogic TR | Immmediate Transfusion Reactions | FNHTR | 0%
|
| IUT Unit Requirements | fresh <7 days old | 0%
|
| High Prevalence Antigen | Gerbich | 0%
|
| Component of rejuvenation solution | Non-Penetrating agents | RBC Storage: Decrease | Glucose | 0%
|
| Penetrating agents | Glycerol | 0%
|
| High Prevalence Antigen | Gregory (Gya) | 0%
|
| IUT Unit Requirements | Group O D-negative | 0%
|
| Additional Serum Procedures in Antibody Identification | Hemagglutinin inhibition | 0%
|
| Population at risk of Hemosiderosis | Hemoglobinopathies | 0%
|
| IUT Unit Requirements | Hgb-S negative | 0%
|
| High Prevalence Antigen | Holley (Hy) | 0%
|
| Non-Penetrating agents | Hydroxyethyl starch | 0%
|
| CPP is deficient in | I | 0%
|
| CPP contains | II | 0%
|
| Population at risk of TA-GVHD | Immunocompromised | 0%
|
| Population at risk of TA-GVHD | Immunodeficient | 0%
|
| Erythrocytapheresis indications | Incompatible RBCs | 0%
|
| Population at risk of TA-GVHD | Infants | 0%
|
| Component of rejuvenation solution | Inosine | 0%
|
| Donation Process | Interview and physical exam | 0%
|
| Delayed Transfusion Reactions | Iron overload or transfusion-induced hemosiderosis | 0%
|
| IUT Unit Requirements | irradiated | 0%
|
| CPP contains | IX | 0%
|
| High Prevalence Antigen | Jacobs (Jra) | 0%
|
| HPA Common in Blacks | Joseph | 0%
|
| High Prevalence Antigen | Joseph (Joa) | 0%
|
| What to do during transfusion reaction? | Keep IV open with saline | 0%
|
| Platelet Storage Increase | Lactate | 0%
|
| RBC Storage: Increase | Lactic acid | 0%
|
| High Prevalence Antigen | Langereis (Lan) | 0%
|
| Additional Red Cell Procedures in Antibody Identification | Lectin Typing | 0%
|
| Parasites that can be Transmitted through Transfusion | Leishmania | 0%
|
| IUT Unit Requirements | leukoreduced | 0%
|
| Erythrocytapheresis indications | Malaria | 0%
|
| Conditions where IUT is necessary | MCA-PSV (>1.5 MoM) | 0%
|
| 2 weeks Referral Due to Vaccination | Measles | 0%
|
| Parasites that can be Transmitted through Transfusion | Microfilaria | 0%
|
| What to do during transfusion reaction? | Monitor or record vital signs | 0%
|
| Platelet Storage Decrease | Morphology | 0%
|
| Low Prevalence Antigen | Mta | 0%
|
| 2 weeks Referral Due to Vaccination | Mumps | 0%
|
| Prevention and Treatment of Hemosiderosis | Neocytes | 0%
|
| Criteria to be Eligible for Computer Crossmatch | no current or past history of clinically significant antibodies | 0%
|
| 2 weeks Referral Due to Vaccination | Oral Polio | 0%
|
| RBC Storage: Shift to the left | Oxygen dissociation curve | 0%
|
| Population at risk of Hemosiderosis | Patient who are transfusion dependent | 0%
|
| What to do during transfusion reaction? | Perform clerical check for ID errors | 0%
|
| CPP cannot be used as a substitute for | PF24 | 0%
|
| Platelet Storage Decrease | RBC Storage: Decrease | pH | 0%
|
| Component of rejuvenation solution | Phosphate | 0%
|
| RBC Storage: Increase | Plasma hemoglobin | 0%
|
| RBC Storage: Increase | Plasma K+ | 0%
|
| Parasites that can be Transmitted through Transfusion | Plasmodium | 0%
|
| Platelet Storage Increase | Platelet activation markers (P-selectin [CD62P] or CD63] | 0%
|
| Platelet Storage Decrease | Platelet aggregation | 0%
|
| Antiplatelet Agent | Plavix | 0%
|
| Non-Penetrating agents | Polyvinylpyrrolidone | 0%
|
| Additional Serum Procedures in Antibody Identification | Prewarming | 0%
|
| Medications that Can Cause Birth Defects | Propecia | 0%
|
| Medications that Can Cause Birth Defects | Proscar | 0%
|
| Delayed Immunologic TR | Delayed Transfusion Reactions | PTP | 0%
|
| Component of rejuvenation solution | Pyruvate | 0%
|
| Solutions Avoided for Dilution of Blood Components | Ringers solution | 0%
|
| Additional Serum Procedures in Antibody Identification | Saline Replacement | 0%
|
| Additional Serum Procedures in Antibody Identification | Serum adsorption | 0%
|
| Population at risk of Hemosiderosis | Sickle cell anemia | 0%
|
| Erythrocytapheresis indications | Sickle cell disease | 0%
|
| Medications that Can Cause Birth Defects | Soriatane | 0%
|
| What to do during transfusion reaction? | Stop the transfusion | 0%
|
| Low Prevalence Antigen | Swann (Swa) | 0%
|
| Immediate Non-Immunulogic TR | Immmediate Transfusion Reactions | TACO | 0%
|
| Delayed Immunologic TR | Delayed Transfusion Reactions | TA-GVHD | 0%
|
| Population at risk of Hemosiderosis | Thalassemia | 0%
|
| CPP cannot be used as a substitute for | thawed plasma | 0%
|
| Antiplatelet Agent | Ticlid | 0%
|
| Additional Serum Procedures in Antibody Identification | Titration | 0%
|
| Parasites that can be Transmitted through Transfusion | Toxoplasma | 0%
|
| Low Prevalence Antigen | Tr | 0%
|
| Immediate Immunulogic TR | Immmediate Transfusion Reactions | TRALI | 0%
|
| Delayed Non-Immunologic TR | Transfusion-induced hemosiderosis | 0%
|
| Immmediate Transfusion Reactions | Transfusion-related adverse events during massive transfusion and physical or chemical during transfusion | 0%
|
| Parasites that can be Transmitted through Transfusion | Trypanosoma | 0%
|
| 2 weeks Referral Due to Vaccination | Typhoid | 0%
|
| Additional Red Cell Procedures in Antibody Identification | Use of AET/DTT | 0%
|
| Additional Serum Procedures in Antibody Identification | Use of sulfhydryl reagents | 0%
|
| Additional Red Cell Procedures in Antibody Identification | Use of ZZAP | 0%
|
| CPP contains | V | 0%
|
| High Prevalence Antigen | Vel (Ve) | 0%
|
| RBC Storage: Decrease | Viable cells | 0%
|
| CPP contains | VII | 0%
|
| CPP is deficient in | VIII | 0%
|
| Component of Cryoprecipitate | VwF | 0%
|
| CPP is deficient in | vWF | 0%
|
| Low Prevalence Antigen | Wright’s antigen | 0%
|
| CPP contains | X | 0%
|
| CPP contains | XI | 0%
|
| CPP is deficient in | XIII | 0%
|
| 2 weeks Referral Due to Vaccination | Yellow Fever | 0%
|
| Antiplatelet Agent | Zontivity | 0%
|